MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
EGF Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
EGF (epidermal growth factor) is a 53-amino-acid, ~6 kDa polypeptide and the prototype ligand of the EGF receptor (EGFR/ErbB1) tyrosine kinase. Binding EGFR activates the PI3K/AKT and MAPK/ERK pathways that drive keratinocyte and fibroblast proliferation, migration and re-epithelialization, making EGF a wound-healing and skin-regeneration signal rather than a metabolic peptide. The best-validated clinical use is Heberprot-P, recombinant human EGF infiltrated intralesionally at 75 mcg three times per week for advanced diabetic foot ulcers, achieving full granulation and high closure rates (PMID 19291119, PMID 25856197). Cosmetic products use topical EGF at roughly 10-50 mcg/mL for wrinkles and photoaging. EGF has a very short half-life and is delivered locally, not systemically. It is approved in Cuba and 15+ countries but is not FDA- or EMA-approved; the subcutaneous reconstitution figures here are an educational measurement reference only.
Reconstitute: Add 2 mL bacteriostatic water → 0.5 mg/mL concentration.
Typical dose: 75 mcg per dose, 3×/week intralesional (25 mcg for smaller lesions); topical 10-50 mcg/mL
Easy measuring: At 0.5 mg/mL, 1 unit = 0.01 mL = 0.0050 mg (5 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder refrigerated at 2-8 °C, or frozen at −20 °C for long-term storage, protected from light. Because EGF is heat- and protease-labile, the reconstituted solution should be kept refrigerated at 2-8 °C and used within a short window (hours to a few days); avoid repeated freeze-thaw cycles and vigorous agitation.
Half-life: Very short in vivo: minutes in serum, ~15-30 min in the protease-rich wound bed, and ~0.6-1.9 h in ocular tissue after local delivery, hence frequent local dosing.
Route: Clinically intralesional/perilesional (Heberprot-P) or topical (cosmetic serums, 10-50 mcg/mL); the subcutaneous reconstitution model here is a measurement reference only.
Status: Approved in Cuba and 15+ countries for diabetic foot ulcers; NOT FDA- or EMA-approved (US clinical trials only). Cosmetic/research use; educational, not medical advice.
About EGF
EGF (epidermal growth factor) is a 53-amino-acid, ~6 kDa polypeptide that binds the EGF receptor (EGFR) to drive keratinocyte and fibroblast proliferation, migration and re-epithelialization, making it a wound-healing and skin-regeneration signal rather than a metabolic or anabolic peptide [1][6]. Its real-world routes are intralesional injection (the Cuban product Heberprot-P) and topical cosmetic application; the subcutaneous reconstitution figures below are an educational measurement reference only, not the clinical route.\n\nThis guide models a 1 mg vial reconstituted with 2 mL of bacteriostatic water (500 mcg/mL) so the clinical doses land on clean, measurable marks on a U-100 insulin syringe: each unit holds 5 mcg, so a 25 mcg dose measures 5 units and the standard 75 mcg dose measures 15 units. In practice these volumes are infiltrated into and around a wound bed, not into subcutaneous fat.\n\nThe established EGF dosage protocol is the Heberprot-P regimen: 75 mcg infiltrated intralesionally and perilesionally three times per week, on alternate days, until the diabetic foot ulcer is fully granulated and closed; a 25 mcg dose is used for smaller or more superficial lesions [2][3][4]. EGF's very short half-life is the reason dosing is repeated and local rather than systemic [5].\n\nFrequency: Three times per week on alternate days, until wound closure. EGF is not FDA- or EMA-approved and is presented here for educational purposes only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe (this yields a 500 mcg/mL solution from a 1 mg vial, or 5 mcg per U-100 unit).
Inject the water slowly down the inner wall of the 1 mg EGF vial; do not aim the stream at the powder, as EGF is a fragile protein that denatures with shear and foaming.
Gently swirl or roll the vial until the solution is completely clear; do not shake. The result is 500 mcg/mL.
Store refrigerated at 2-8 °C and draw the units for your dose (25 mcg = 5 units, 75 mcg = 15 units on a U-100 syringe).
Educational note: EGF is clinically infiltrated INTO and AROUND a wound (intralesional/perilesional) or applied TOPICALLY at 10-50 mcg/mL, not injected into subcutaneous fat; these subcutaneous figures are a measurement reference only.
Interactive EGF Syringe Calculator
Currently visualizing the 1 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 1mg dry powder in 2mL water yields 0.50 mg/mL. To evaluate a 250mcg dose, pull to 50.0 units (50 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Smaller / superficial lesions (lower-dose protocol) | 25 mcg | 5 units (0.05 mL) |
| Standard advanced diabetic foot ulcer dose | 75 mcg | 15 units (0.15 mL) |
| Maintenance, 3×/week until wound closure | 75 mcg | 15 units (0.15 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 1 mg vial.
Peptide Vials (EGF, 1 mg each):
- check8-week course (24 doses at 75 mcg, 3×/week ≈ 1.8 mg total): about 2 vials.
- check12-week course (36 doses ≈ 2.7 mg total): about 3 vials.
- check16-week course (48 doses ≈ 3.6 mg total): about 4 vials.
- checkAdd one extra vial to cover reconstitution dead-volume and dosing waste.
Insulin Syringes (U-100):
- checkOne sterile syringe per injection: about 24 for 8 weeks, 36 for 12 weeks, and 48 for 16 weeks.
- checkEach 75 mcg dose draws 15 units; each 25 mcg dose draws 5 units at 500 mcg/mL.
- checkAdd roughly 10% extra for drawing errors and dropped needles.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- check2 mL per 1 mg vial: about 4 mL for 8 weeks, 6 mL for 12 weeks, and 8 mL for 16 weeks.
- checkA single 30 mL bottle comfortably covers a full 16-week course.
- checkDiscard an opened bottle after about 28 days or per the product label.
Alcohol Swabs:
- checkTwo swabs per injection (vial septum plus skin): about 48 for 8 weeks, 72 for 12 weeks, and 96 for 16 weeks.
- checkA single 100-count box covers roughly one 16-week course.
- checkKeep spares for wiping the work surface and re-capping the vial.
Mechanism of Action (MOA)
EGF is a single-chain, 53-amino-acid polypeptide of about 6 kDa, stabilized by three intramolecular disulfide bonds. It was first isolated from mouse submaxillary gland by Stanley Cohen, who observed that the extract triggered precocious eyelid opening and tooth eruption in newborn mice, effects traced to accelerated epidermal cell proliferation, work recognized with the 1986 Nobel Prize in Physiology or Medicine [1]. Recombinant human EGF (rhEGF) is now produced in yeast or bacteria for clinical and cosmetic use.\n\nEGF acts by binding the extracellular domain of the epidermal growth factor receptor (EGFR/ErbB1), a ~170 kDa transmembrane receptor tyrosine kinase expressed on keratinocytes, fibroblasts and endothelial cells. Ligand binding drives receptor dimerization and autophosphorylation, switching on the PI3K/AKT, RAS-MAPK/ERK and JAK/STAT cascades that govern cell proliferation, migration, differentiation and survival [6]. In skin, this accelerates re-epithelialization, granulation-tissue formation and angiogenesis, the core of cutaneous repair [3][6]. Genetic loss of EGFR signaling markedly delays wound closure, underscoring how central the pathway is to healing.\n\nThe leading clinical application exploits this biology locally. Diabetic foot ulcers feature a protease-rich, growth-factor-depleted wound bed; native EGF is low and exogenous EGF is degraded within minutes. Heberprot-P, a Cuban rhEGF formulation, is therefore infiltrated directly into and around the ulcer (intralesional and perilesional) at 75 mcg three times per week, replenishing the growth factor at the site faster than proteases can clear it and stimulating full granulation and closure [2][3][4].\n\nPharmacokinetics explain the dosing rhythm. EGF has a very short in-vivo half-life: on the order of minutes in serum, roughly 15-30 minutes in the proteolytic wound environment, and about 0.6-1.9 hours across ocular tissues after local delivery [5]. Its large, charged structure also limits passive skin penetration, so topical cosmetic products (typically 10-50 mcg/mL, about 1-5 ppm) depend on microneedling, micro-spicules, liposomes or other delivery aids to reach viable epidermis [7][8]. These short-half-life and poor-penetration constraints are why no practical systemic EGF dose exists; clinically meaningful exposure is achieved by repeated local infiltration or assisted topical delivery, not by injection into fat or muscle.\n\nThe subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site. In the real world EGF is delivered intralesionally (Heberprot-P) or topically (cosmetic serums); it is not a subcutaneous fat-loss or muscle-building peptide and does not act on the growth-hormone/IGF-1 axis. Modeling a 1 mg vial in 2 mL of bacteriostatic water (500 mcg/mL) simply makes the clinical 25-75 mcg doses easy to visualize on a U-100 syringe at 5 mcg per unit.
Clinical Trial Efficacy Highlights
- starStanley Cohen's discovery and characterization of EGF, recognized with the 1986 Nobel Prize in Physiology or Medicine, established that this 53-amino-acid polypeptide accelerates epidermal cell proliferation in vivo (precocious eyelid opening and tooth eruption in newborn mice) and defined the EGF/EGFR signaling system that underpins all subsequent therapeutic use [1].
- starFernández-Montequín and colleagues (Int Wound J, 2009) treated 20 patients with chronic diabetic foot ulcers using intralesional Heberprot-P 75 mcg three times per week until closure; full granulation was achieved in all 20 patients in 23.6 ± 3.8 days, complete wound closure in 17 (85%) within 44.3 ± 8.9 days, and no amputation was required [3].
- starDumantepe and colleagues (Growth Factors, 2015) gave intralesional rhEGF 75 mcg three times per week for 5-8 weeks to 17 patients with chronic diabetic foot ulcers; complete granulation occurred in all 17 in about 32 days and wound closure in 94.1% (16/17) in roughly 53 days, with only one relapse over one year of follow-up [4].
- starBerlanga-Acosta and colleagues (MEDICC Rev, 2013) summarized the development of Heberprot-P, noting that diabetic wounds are growth-factor-depleted and that repeated peri- and intra-lesional infiltration of rhEGF enhances healing of recalcitrant ulcers; the product was registered in Cuba in 2006 and has since treated more than 100,000 patients across multiple countries [2].
- starMiller-Kobisher and colleagues (J Cutan Aesthet Surg, 2021) systematically reviewed EGF in aesthetics and regenerative medicine, reporting an 87.9% wound-closure rate for diabetic foot ulcers with intralesional injection and, on the cosmetic side, 73.4% improvement in melasma with a topical serum applied twice daily for 8 weeks, plus benefit for wrinkles, acne and stretch marks [7].
- starHa and colleagues (Ann Dermatol, 2017) compared a soluble micro-spicule EGF delivery vehicle with EGF alone for periocular wrinkles; the micro-spicule group showed a 30.1% increase in dermal density and a 19.5% increase in dermal depth from baseline, with 70% participant satisfaction versus 50% in the control group and only transient erythema reported [8].
- starA 2023 dermatology review (Shin et al., Int Wound J) summarized rhEGF use for diabetic foot ulcers, burns, pressure sores and radiation dermatitis, attributing efficacy to EGFR-driven PI3K/AKT and ERK/MAPK signaling and noting there is no evidence that topical rhEGF preparations stimulate cancer-cell proliferation [6].
- starPharmacokinetic work by Chan and colleagues (Invest Ophthalmol Vis Sci, 1991) measured EGF tissue half-lives after local ocular delivery of roughly 0.6-1.9 hours, consistent with EGF's rapid clearance and providing the mechanistic rationale for frequent, locally delivered dosing rather than single or systemic administration [5].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningIn the intralesional diabetic-foot-ulcer trials, the most frequent adverse events were tremors (around 55%), chills (around 40%), pain and a burning sensation at the injection site (around 25% each), and local infection (around 20%), with less common weakness, fever, headache and transient hypotension [3][4].
- warningLocal injection reactions (pain, erythema, odor and burning at the infiltration site) are expected with intralesional dosing; the procedure is performed under medical supervision with wound debridement and infection control.
- warningTopical cosmetic EGF is generally well tolerated; the most common effects are transient erythema or irritation, and micro-spicule or microneedle delivery systems can cause short-lived redness at the application site [8].
- warningBecause EGFR is overexpressed in many epithelial cancers and EGF stimulates cell proliferation, EGF should not be applied to or injected near undiagnosed, suspicious or malignant lesions; although reviews report no evidence that topical rhEGF stimulates cancer-cell proliferation, EGF is best avoided in people with active malignancy or premalignant skin lesions [6].
- warningContraindications include known hypersensitivity to the formulation; intralesional use is reserved for appropriately staged wounds under clinical care and is not a self-administered procedure.
- warningEGF is heat- and protease-labile and has a very short half-life; improper storage, freeze-thaw cycling or vigorous shaking can destroy its activity, so a product handled poorly may be biologically inert rather than harmful.
- warningEGF is not a systemic, anabolic or fat-loss peptide and does not act on the growth-hormone/IGF-1 axis; there is no validated subcutaneous dosing protocol, and the figures on this page are an educational measurement reference only.
- warningRegulatory and research status: Heberprot-P (intralesional rhEGF) is approved in Cuba and more than a dozen countries but is NOT FDA- or EMA-approved; in the United States it remains in clinical trials. Cosmetic and research-grade EGF is sold for topical cosmetic or laboratory use only. This content is educational and is not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical EGF dosage?expand_more
The best-validated clinical EGF dosage is the Heberprot-P regimen for advanced diabetic foot ulcers: 75 mcg of recombinant human EGF infiltrated intralesionally and perilesionally three times per week, on alternate days, until the wound closes; a 25 mcg dose is used for smaller or superficial lesions (Fernández-Montequín 2009, Dumantepe 2015). For cosmetic and dermatologic use, EGF is applied topically at roughly 10-50 mcg/mL (about 1-5 ppm). There is no established systemic or subcutaneous EGF dose; the subcutaneous figures on this page (25 mcg = 5 units, 75 mcg = 15 units at 500 mcg/mL) are an educational measurement reference only.
Is EGF FDA approved?expand_more
No. Heberprot-P, the intralesional recombinant human EGF product for diabetic foot ulcers, is approved in Cuba (registered 2006) and more than a dozen other countries, but it is not approved by the FDA or the EMA. In the United States it remains in clinical trials, not on the market. Topical and research-grade EGF is sold as a cosmetic ingredient or for laboratory use, not as an approved drug. This page is educational and is not medical advice.
What is the half-life of EGF?expand_more
EGF has a very short in-vivo half-life. It is cleared from serum within minutes, degraded in roughly 15-30 minutes in the protease-rich environment of a chronic wound, and shows tissue half-lives of about 0.6-1.9 hours after local ocular delivery (Chan 1991). This rapid clearance, combined with poor passive skin penetration of a ~6 kDa charged protein, is exactly why effective protocols use repeated local infiltration (Heberprot-P, three times per week) or delivery-assisted topical application rather than a single or systemic dose.
How is EGF reconstituted and administered?expand_more
Clinically, Heberprot-P is reconstituted and infiltrated directly into and around the wound bed (intralesional/perilesional), and cosmetic EGF is applied topically, so neither uses subcutaneous fat injection. For the educational model on this site, a 1 mg vial is mixed with 2 mL of bacteriostatic water to give 500 mcg/mL: draw the water slowly down the vial wall, swirl gently until clear (never shake, as EGF is fragile), and refrigerate. At that concentration each U-100 unit holds 5 mcg, so a 25 mcg dose is 5 units and the standard 75 mcg dose is 15 units.
Can EGF be stacked or combined with other peptides?expand_more
In cosmetic formulations EGF is frequently combined with other growth factors, copper peptides, hyaluronic acid or repair peptides, and in research settings it is studied alongside wound-healing agents. However, there is no validated clinical stacking protocol, and EGF works on the EGFR pathway, not the growth-hormone/IGF-1 axis, so it is pharmacologically unrelated to GH secretagogues. Because EGF stimulates epithelial cell proliferation, any combination near suspicious or malignant lesions should be avoided. Treat any combination as experimental and educational only.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing EGF, plus the universal dosing calculator.
Academic References & Study Citations
The Nobel Prize in Physiology or Medicine 1986 — awarded to Stanley Cohen and Rita Levi-Montalcini for their discoveries of growth factors (epidermal growth factor and nerve growth factor). Press release, Nobel Assembly at the Karolinska Institute. View Scientific Paper →
Berlanga-Acosta J, Fernández-Montequín J, Valdés-Pérez C, et al. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. MEDICC Rev. 2013;15(1):11-15. PMID: 23396236. View Scientific Paper →
Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72. PMID: 19291119. View Scientific Paper →
Dumantepe M, Fazliogullari O, Seren M, Uyar I, Basar F. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers. Growth Factors. 2015;33(2):128-132. PMID: 25856197. View Scientific Paper →
Chan KY, Lindquist TD, Edenfield MJ, Nicolson MA, Banks AR. Pharmacokinetic study of recombinant human epidermal growth factor in the anterior eye. Invest Ophthalmol Vis Sci. 1991;32(13):3209-3215. PMID: 1748552. View Scientific Paper →
Shin SH, Koh YG, Lee WG, Seok J, Park KY. The use of epidermal growth factor in dermatological practice. Int Wound J. 2023;20(6):2414-2423. doi:10.1111/iwj.14075. PMC10333026. View Scientific Paper →
Miller-Kobisher B, Suárez-Vega DV, Velazco de Maldonado GJ. Epidermal Growth Factor in Aesthetics and Regenerative Medicine: Systematic Review. J Cutan Aesthet Surg. 2021;14(2):137-146. PMC8423211. View Scientific Paper →
Ha JM, Lim CA, Han K, et al. The Effect of Micro-Spicule Containing Epidermal Growth Factor on Periocular Wrinkles. Ann Dermatol. 2017;29(2):187-193. PMC5383744. View Scientific Paper →